Step 1: is the movement disorder really tremor?

The first step in diagnosing tremor is the identification of hyperkinetic movements as ‘tremulous’. Tremor is defined as an involuntary, rhythmic, oscillatory movement of a body part.2 The most important alternative diagnosis is myoclonus, especially high frequency cortical myoclonus (e in familial cortical myoclonus), polyminimyoclonus (eg, in multiple system atrophy), peripheral myoclonus (which sometimes occurs in inflammatory neuropathies or radiculopathies) or asterixis (a negative myoclonus that looks like a flapping tremor of the hands when the wrists are extended).4 5 Moreover, the rhythmic, low-frequency jerks in ongoing focal epilepsy (epilepsia partialis continua) can be misinterpreted as unilateral jerky rest tremor.4 Generally, a ‘jerky’ aspect ought to raise suspicion of myoclonus as the movement disorder in question, rather than tremor. However, the distinction between high frequency myoclonus and tremor on the basis of ‘rhythmicity’ is complicated by the fact that tremor is almost never perfectly rhythmic. In fact, a jerky or irregular aspect is part of the characteristic phenotype of some tremor syndromes, such as dystonic tremor or Holmes tremor.6 When in doubt, polymyography can be used to differentiate between myoclonus and tremor: polymyography is further described in step 3. Naturally, tremor and myoclonus are not mutually exclusive: patients can have both movement disorders.

Step 2: characterise the tremor clinically

The neurological examination is the key tool to establish a clinical tremor syndrome, that is, an axis 1 classification. This is of crucial importance, as the tremor syndrome is used in later steps to guide our choices for diagnostic tests to elucidate the underlying aetiology (ie, an axis 2 classification). In figure 2, we propose a practical clinical algorithm that helps to accurately diagnose a tremor syndrome. Before entering this algorithm, it is useful to characterise the tremor using the features outlined in box 1. The algorithm contains decision points in an order that facilitates ‘short-cuts’ to the diagnosis of a clinical tremor syndrome.

• Download figure
• Open in new tab
• Download powerpoint

Figure 2

Practical clinical algorithm. Isolated tremor syndromes are depicted in blue on the left side of the diagram, combined tremor syndromes in orange on the right side. Functional tremor is depicted in green on the right side. *For example, mildly unsteady tandem gait, questionably abnormal posturing of a body part, mild cognitive impairment, questionable bradykinesia or rigidity and other mild neurological signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. †For example, anxiety, fatigue, thyrotoxicosis, hypoglycaemia, pheochromocytoma, tremor-provoking medication (see table 1).

First, it is useful to look for signs of a functional movement disorder. Tremor is a common phenotype of functional movement disorders.7 Signs to investigate are entrainment (evaluate whether the tremor frequency changes when the patient performs a contralateral finger tapping task), distractibility (cessation of tremor on distraction by a mental or contralateral movement task) and temporary arrest of tremor during a ballistic pointing test of the other hand (‘pointing test’). Inability to perform a simple cognitive task can also be a sign of a functional movement disorder, as well as a sudden onset of the tremor.8 Sometimes marked fluctuations of the frequency of a functional tremor (between different contexts or spontaneously) can be noticed by visual inspection alone, otherwise polymyography can be used (step 3). Finally, the examiner may influence the co-contraction pattern by moving the patient’s hand passively and note whether or not the tremor fluctuates in parallel to the muscle tone.9 This can be done during clinical assessment or during polymyography (allowing a quantification of muscle contraction and tremor amplitude). An important pitfall is that functional movement disorders may occur in patients who also have an organic movement disorder.

Second, we suggest looking for so-called ‘prominent additional signs’. This distinction is important, because tremor can occur in isolation (isolated tremor syndromes) or together with other neurological signs (combined tremor syndromes). A distinction is made between ‘prominent additional signs’ and so-called ‘signs of uncertain significance’.2 The first are clear neurological signs, used to define a combined tremor syndrome, such as bradykinesia, cerebellar signs, dystonic posturing, signs of peripheral neuropathy and brainstem signs. Examples of ‘signs of uncertain significance’ include a mildly unsteady tandem gait, questionably abnormal posturing of a body part, mild cognitive impairment, questionable bradykinesia or rigidity and other mild neurological signs that do not suffice to make an additional syndrome classification.2 As can be seen in the algorithm, the weight placed by the clinician on an additional symptom (such as dystonic posturing of a limb) determines whether a tremor is called dystonic tremor or ET ‘plus’. This can be difficult, as outlined under ‘Isolated tremor syndromes’ section.

Step 3: is polymyography indicated?

Polymyography can be used to support the suspected clinical diagnosis or advance the clinical characterisation of the tremor. However, the value depends on the skills and experience of the neurophysiologist. Therefore, the availability of polymyography varies between centres and the quality is highest in specialised clinics. This can be a reason for referral of particularly difficult cases. There are a number of specific situations in which it can be of help.

First, polymyography can be used to make the distinction between tremor and myoclonus. Look for characteristics of (cortical) myoclonus such as 1) short electromyogram (EMG) bursts (<50–100 ms), 2) at an irregular frequency, 3) in a synchronous agonist-antagonist contraction pattern, 4) or transient loss of muscle tone (negative myoclonus). More advanced techniques, such as back-averaging and coherence analysis, include a combination of EMG and electroencephalogram (EEG) in search for signs of cortical drive.39–41 It should be borne in mind that epilepsia partialis continua is not always associated with epileptic EEG activity: in ±17% of cases, the ictal EEG is normal.42

A second useful application is the objective assessment of signs associated with functional tremor, such as entrainment and distractibility (step 2). Functional tremor can present as an alternating tremor or as a co-contraction tremor. A co-contraction tremor (where agonist and antagonist muscles increase limb stiffness, resulting in a fine, high-frequency tremor) can be more resistant to entrainment and distraction. In these cases, polymyography can be used to identify the co-contraction pattern, which is typically present at the onset of posturing. Furthermore, the pointing test is often positive in co-contraction tremor, and polymyography is more sensitive to detect this than the clinical eye. In 2016, a test battery was validated as laboratory-supported criteria for the diagnosis of functional tremor, including an increase of tremor amplitude on loading, tonic discharge of antagonist muscles approximately 300 ms before tremor onset, entrainment or increase in variability and change of tremor frequency while tapping with the contralateral hand, less accurate tapping performance at requested frequencies, significant interlimb coherence in bilateral tremors and transient arrest of tremor during ballistic movements of the other hand.43 By application of this test battery at a cut-off score of ≥3/10 points, functional tremor can be distinguished from organic tremor with a sensitivity of 90% and a specificity of 96%. While many of these tests can be done clinically, polymyography is usually more sensitive and in some cases necessary, for example, for calculating coherence. Moreover, spontaneous and marked (>1 Hz) variability in tremor frequency throughout the registration is also a marker of functional tremor.28 44 It is important to appreciate that while most tests for functional tremor have a high specificity, none are 100% specific. In other words, ‘functional’ characteristics can occasionally occur in otherwise ‘organic’ tremor, and it is of course possible that an existing organic tremor is aggravated by functional tremor. Complimentary to the establishment of functional characteristics, polymyography can be an important identifier of tremor with an unusual clinical appearance. These unusual tremors are sometimes incorrectly recognised as functional tremor, as can happen in lesion-based tremors such as Holmes tremor or myorhythmia.45

A third use of polymyography is to differentiate between EPT and ET. EPT has mechanical and mechanical-reflex components but only rarely central components (±10%), while ET has a central origin. Mechanical components are body part oscillations that are driven by factors such as cardiac systole, breathing and irregularities in muscle contraction. These mechanical components may trigger a reflex response in the muscle under certain circumstances (eg, fatigue, stress, intake of adrenergic medication). The resulting tremor can be influenced by mechanical factors such as inertial loading or by changing the movement tasks or postures. This introduces changes in stiffness or the contribution of different joints, which influences the tremor frequency. If a change in these factors leads to a change in tremor frequency, this points towards EPT.46 A decrease in tremor frequency after inertial loading is a specific finding47 48 (see Longardner et al for an instructional video on how to conduct this test properly).49 A higher frequency (>8 Hz) also points towards EPT.

Finally, polymyography may be helpful when selecting appropriate muscles for botulinum toxin treatment in patients with (dystonic) tremor. Polymyography can also confirm the low frequency (<5 Hz) that is typical of Holmes tremor, as frequency is difficult to judge by eye.50 51

Step 4: is the tremor medication or toxin induced?

After clinical phenotyping as described in steps 1–3, the next steps provide a systematic way to search for an aetiology. Use of tremorgenic medication is a common cause of mainly enhanced physiological and parkinsonism-associated tremor: the tremor emerges after the start or dose escalation of the offending drug and vanishes usually shortly after discontinuation.52 An overview of medicines and toxins that are known to cause tremor is provided in table 1.53 A tremor produced by lithium, antidepressants or toxins frequently has the clinical appearance of rhythmic cortical myoclonus. Exposure to toxins is common in certain occupations and tremor can be the first manifestation in a constellation of exposure toxicity signs and symptoms. It is important to recognise these acquired causes of tremor, because reduction or removal of the medication or toxic agent is the first step in treating these patients.

Step 5: are laboratory tests indicated aimed at an acquired cause or treatable metabolic disorder?

Tremor and myoclonus can be caused by forms of organ failure or homeostatic imbalance, such as renal failure, hepatic failure, hyperthyroidism and disturbed glucose metabolism. These causes are important to identify, as treatment leads to cessation of tremor. Basic laboratory testing is therefore advised, especially in patients with a bilateral isolated tremor syndrome, and this should include thyroid, liver and renal function, glucose and electrolytes. The exact yield of these tests is, however, unknown. Other tests should only be performed when they are specifically indicated, to minimise unsolicited findings. In isolated tremor, investigate serum catecholamines if there are other symptoms of pheochromocytoma (ie, episodes of headache, sweating and/or tachycardia).54 Test for toxins when there is a history of exposure.53 In tremor combined with dystonia or a family history of movement disorders and cognitive or psychiatric symptoms, consider testing copper and iron metabolism (serum copper, ceruloplasmin, iron, ferritin) as this can point to Wilson disease55 or neurodegeneration with brain iron accumulation56 (particularly neuroferritinopathy). Apart from Wilson disease, there are other treatable metabolic diseases that typically present with dystonia or ataxia but in which patients are occasionally reported to have tremor. These include Niemann-Pick type C, glutaric aciduria type 1, ataxia with vitamin E deficiency, Segawa disease and coenzyme Q10 deficiency (table 1).57–59 In case of a tremor associated with neuropathy, test for acquired causes, including paraproteinemia.

Step 6: is an MRI indicated?

A cerebral MRI scan is worthwhile when the differential diagnosis includes an aetiology resulting in structural abnormalities. As a guiding principle, we propose to perform an MRI in patients with a combined tremor syndrome that is 1) focal/unilateral, 2) non-classical in appearance, 3) in case there is a sudden onset or stepwise deterioration or 4) a family history of movement disorders combined with cognitive or psychiatric symptoms. The latter suggests a heritable neurodegenerative or metabolic disorder, which can sometimes be identified using MRI. Look for lesions or atrophy in the basal ganglia, cerebellum and brainstem. Based on the clinical characteristics identified in step 2, specific signs to look for include hummingbird sign, morning glory sign and hot cross bun sign in atypical parkinsonism60 (combined with bradykinesia); panda sign in Wilson disease61 (combined with dystonia) and middle cerebral peduncle and splenium sign in fragile X-associated tremor ataxia syndrome (FXTAS, combined with ataxia).22 62 Generally, patients with an isolated tremor syndrome will have normal MRI scans and thus structural imaging is not indicated. However, this rule of thumb should be abandoned in isolated patients with tremor in case of either hints at an acquired cause (sudden onset or stepwise deterioration, unilateral tremor), or a family history of movement disorders combined with cognitive or psychiatric symptoms. A brain MRI is unnecessary to diagnose a functional tremor, but we recognise that it is sometimes needed to reassure a patient who has remaining fears about an alternative diagnosis despite the neurologist’s explanation.63

Step 7: is presynaptic dopamine transporter imaging indicated?

Presynaptic dopamine transporter imaging (123I-FP-CIT SPECT (DaT-SPECT)) can be helpful in some patients with tremor. Dopamine receptor imaging (such as F-DOPA PET) can also be used, but this is much less common in most clinics. Here, we propose guiding principles on indications for nuclear imaging: these are not extensively evidence-based due to a lack of good data and the absence of gold standard for many tremor syndromes. Because this technique is aimed at assessing the presence of a presynaptic dopaminergic deficit, it will only be relevant if we wish to differentiate tremor related to parkinsonism from other tremor syndromes, and considerable doubt remains after steps 1–6 have been taken. More specifically, presynaptic dopamine transporter imaging is well suited to distinguish between parkinsonism-associated tremor and ET,64 and dystonic tremor, which can be a cause of scans without evidence of dopaminergic deficit in suspected patients with PD.65 However, although presynaptic dopamine transporter imaging is used to distinguish drug-induced parkinsonism from neurodegenerative forms of parkinsonism,66 it cannot reliably make a distinction between the different causes of a parkinsonism-associated tremor.67

Step 8: are genetic tests indicated?

Genetic testing can be considered but should be limited to particular situations. There are several genetic mutations that can cause a clinical syndrome that includes tremor. However, in a patient presenting with isolated tremor, there is currently no indication for genetic testing as no disease-causing genes are known for isolated tremor syndromes. This underlines the importance of clinical examination and particularly the differentiation in isolated versus combined tremor syndromes, as depicted in figure 2.

Genetic testing can be considered in patients with a combined tremor and a family history of movement disorders, cognitive symptoms, psychiatric symptoms or neuropathy. For instance, a familial syndrome consisting of tremor and ataxia could point towards FXTAS68 or a spinocerebellar atrophy (SCA).69 In Klinefelter syndrome, a predominantly postural and kinetic tremor has been described, sometimes with dystonic features.70 More rarely, a combination of tremor and ataxia can be found in patients with adult ataxia telangiectasia71 or inborn errors of metabolism such as Niemann-Pick type C72 (figure 2). Tremor can also be a feature in the clinical presentation of some of the early onset/familial parkinsonisms.73 In familial cases of tremor and dystonia, DYT3 (Lubag’s disease)74 and DYT24 (ANO3)75 can be considered, as well as metabolic disorders (table 2). Particularly consider Wilson disease55 and Niemann-Pick type C if the movement disorders coincide with cognitive or psychiatric symptoms. Moreover, in patients with familial neuropathy and tremor, several Charcot-Marie-Tooth variants are possible,19 as well as spinal bulbar muscle atrophy (Kennedy’s disease).76 Overall, these examples illustrate that genetic testing is only feasible in patients with a combined tremor syndrome and a relevant family history.

In some instances, a particular genetic diagnosis will be suspected and tested by means of conventional Sanger sequencing, but if the list of possible genes is long next-generation sequencing will be the method of choice. This can be done either by using whole-genome sequencing (WGS), whole exome sequencing (WES) or targeted resequencing (TRS) panels that focus on a selection of known disease-causing genes. An advantage of diagnostic gene panels over WGS and WES is that it evades the dilemmas connected to the discovery of unsolicited findings. However, a targeted gene panel needs to be continuously updated with regard to newly established disease genes to be equally effective as WGS or WES, and a tremor gene panel may not be in place. Moreover, be aware that next-generation sequencing is not sensitive for repeat expansions (such as FXTAS, SCAs) and mitochondrial DNA mutations (such as sensory ataxia with neuropathy, dysarthria and ophthalmoparesis). Currently, the cost of next-generation sequencing techniques is falling rapidly and comparable to that of sequencing three individual genes. For further guidance, we advise soliciting a clinical geneticist for patients in whom genetic testing is indicated.